Does elective re-siting of intravenous cannulae decrease peripheral thrombophlebitis? A randomized controlled study.
BACKGROUND
Peripheral venous thrombophlebitis (PVT) is a common complication of intravenous cannulation, occurring in about 30% of patients. We evaluated the effect of elective re-siting of intravenous cannulae every 48 hours on the incidence and severity of PVT in patients receiving intravenous fluids/drugs.


METHODS
We randomized 42 patients who were admitted for major abdominal surgery to either the control or study group (n = 21 in either group). Informed consent was obtained from all of them. Cannulae in the control group were removed only if the site became painful, the cannula got dislodged or there were signs and symptoms suggestive of PVT, namely pain, erythema, swelling, excessive warmth or a palpable venous cord. Cannulae in the study group were changed and re-sited electively every 48 hours. All the patients were examined every 24 hours for signs and symptoms of PVT at the current and previous sites of infusion.


RESULTS
The incidence of PVT was 100% (21/21) in the control group and only 9.5% (2/21) in the study group (p < 0.0001). The severity of PVT was also less in the study group compared with that in the control group. Day-wise correlation of the incidence of PVT showed that 82.6% of the episodes of PVT occurred on day 3.


CONCLUSIONS
Elective re-siting of intravenous cannulae every 48 hours results in a significant reduction in the incidence and severity of PVT. We recommend that this should be adopted as standard practice in managing all patients who require prolonged intravenous therapy.
Nishanth
S
S
Department of Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry 605006, India.
Sivaram
G
G
Kalayarasan
R
R
Kate
Vikram
V
Ananthakrishnan
N
N
D000328:Adult; D000368:Aged; D002406:Catheterization, Peripheral / Q000379:methods*; D017558:Elective Surgical Procedures / Q000379:methods; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013924:Thrombophlebitis / Q000517:prevention & control*